Workflow
Thermage
icon
Search documents
Bausch Health(BHC) - 2025 Q3 - Earnings Call Transcript
2025-10-29 22:02
Bausch Health (NYSE:BHC) Q3 2025 Earnings Call October 29, 2025 05:00 PM ET Company ParticipantsMike Nedelcovych - Director Equity ResearchJJ Charhon - CFOLiwen Wang - Equity Research AssociateTom Appio - CEOLes Sulewski - VPGaren Sarafian - VP of Investor RelationsConference Call ParticipantsNone - AnalystNone - AnalystDoug Miehm - Healthcare AnalystMichael Freeman - Equity Research AnalystOperatorGreetings and welcome to the Bausch Health third quarter 2025 earnings conference call. At this time, all part ...
Bausch Health(BHC) - 2025 Q3 - Earnings Call Transcript
2025-10-29 22:02
Bausch Health (NYSE:BHC) Q3 2025 Earnings Call October 29, 2025 05:00 PM ET Company ParticipantsMike Nedelcovych - Director Equity ResearchJJ Charhon - CFOLiwen Wang - Equity Research AssociateTom Appio - CEOLes Sulewski - VPGaren Sarafian - VP of Investor RelationsConference Call ParticipantsNone - AnalystNone - AnalystDoug Miehm - Healthcare AnalystMichael Freeman - Equity Research AnalystOperatorGreetings and welcome to the Bausch Health third quarter 2025 earnings conference call. At this time, all part ...
Bausch Health(BHC) - 2025 Q3 - Earnings Call Transcript
2025-10-29 22:00
Bausch Health (NYSE:BHC) Q3 2025 Earnings Call October 29, 2025 05:00 PM ET Speaker5Greetings and welcome to the Bausch Health third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. You may be placed into the question queue at any time by pressing star one on your telephone keypad. If anyone should require operator assistance, please press star zero. As a reminder, this conference is being reco ...
乐普医疗_业绩回顾_2025 年三季度营收不及预期但净利润符合预期;目标价上调至 19 元人民币;买入
2025-10-27 12:06
27 October 2025 | 1:10PM CST Equity Research Lepu (300003.SZ): Earnings review: 3Q25 sales missed while NP in line; TP up to Rmb19; Buy Lepu released its 3Q25 results on Oct 24, 2025. Its revenue (Rmb1,569mn, +12% yoy) missed GSe (Rmb1,937mn) due to softer sales of its pharmaceutical business (+53% yoy vs GSe +70%). However, as the company's selling expense ratio was lower than GSe (17.3% vs GSe 21.6%), the company's net profit (Rmb291mn, +176% yoy) was in line with GSe (Rmb277mn). The company highlighted i ...